FINWIRES · TerminalLIVE
FINWIRES

Sector Update: Health Care Stocks Gain Thursday Afternoon

By

-- Health care stocks rose Thursday afternoon with the NYSE Health Care Index climbing 2.5% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.

The iShares Biotechnology ETF (IBB) advanced 2%.

In corporate news, Eli Lilly (LLY) raised its full-year outlook and reported Q1 results above market estimates as sales of Mounjaro more than doubled. Lilly shares jumped 10%.

The US Food and Drug Administration is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances. Eli Lilly makes tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) makes semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Novo shares rose 5.0%.

NovoCure (NVCR) shares surged 28% after the company posted Q1 results.

Related Articles

Australia

Axos Financial Fiscal Q3 Earnings, Revenue Rise

Axos Financial (AX) reported fiscal Q3 earnings late Thursday of $1.90 per diluted share, up from $1.81 a year earlier.Analysts polled by FactSet expected $2.13.Revenue in the three months ended March 31 rose to $392.2 million from $308.8 million a year earlier.Analysts surveyed by FactSet expected $372.5 million.Axos shares fell 2.5% in after-hours trading.

$AX
Insider Trading

HBT Financial Insider Sold Shares Worth $455,416, According to a Recent SEC Filing

Fred L Drake, 10% Owner, Director, Executive Chairman, on April 28, 2026, sold 15,742 shares in HBT Financial (HBT) for $455,416. Following the Form 4 filing with the SEC, Drake has control over a total of 17,270,558 common shares of the company, with 14,343 shares held directly and 17,256,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/775215/000178953026000008/xslF345X05/wk-form4_1777581363.xml

$HBT
Mining & Metals

CN Says Union Pacific-Norfolk Southern Merger Fails To Address Competitive Harms

Canadian National Railway (CNR.TO, CNI) after the close Thursday said it is reviewing Union Pacific UNP) and Norfolk Southern's (NSC) amended merger application submitted to the Surface Transportation Board (STB) and will remain "actively engaged" in this process.According to a statement, the applicants have failed to "materially improve the amended application" in ways that address the competitive harms of the merger. They have not remedied the "significant competitive harms" posed by the merger, nor have they offered any meaningful competitive enhancements as required under the board's new rules, said CN, adding that "these failures should be fatal to the application"."Given the magnitude of this transaction, the board's authority to impose conditions that protect competition and the public interest must be paramount. If Union Pacific and Norfolk Southern have set a cost cap on the conditions they're willing to accept, that's their business decision and their risk. It is not a ceiling on the board's authority, and it doesn't limit what's required in the public interest," said Olivier Chouc, CN's chief legal officer.CN Rail shares closed up C$4.66 at C$152.57 on Toronto Stock Exchange.

$CNI$CNR.TO$NSC$UNP